Ideaya Biosciences Inc (IDYA) fair value: what the stock is really worth
As of Nov 16, 2026: fair value (intrinsic value) of Ideaya Biosciences Inc stock $19.49, price $30.36, that is 35.8% below the price, quality 39 out of 100. Rating: strongly overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
Ideaya Biosciences Inc
IDYA · USFar too expensive (fair value 36% below the price) and weak company, but rising price: meets 1 of 3 rules.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 17, 2026.
How to read this chart
60‑month range $8.28 – $47.13 · fair‑value band $14.62 – $24.37 · the $30.36 price screens above the $19.49 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 17, 2026.
Every Wednesday you see whether Ideaya Biosciences is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
IDEAYA Biosciences, Inc., a precision medicine oncology company, develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States.
Show moreShow less
The company offers Darovasertib, an oral, potent, and selective protein kinase, C (PKC) inhibitor for the treatment of uveal melanoma, ocular cancer, and is being evaluated in multiple clinical trials as monotherapy and in combination with crizotinib for metastatic, neoadjuvant, and adjuvant settings.
The company also offers IDE849, a DLL3 antibody drug conjugate inhibitor for the treatment of SCLC and neuroendocrine carcinomas; IDE034, a B7H3/PTK7 topo-I-payload bispecific BsADC; IDE161, a poly ADP-ribose glycohydrolase inhibitor; IDE705 (GSK101), a Poly Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other mutations associated with HRD; IDE397, a MAT2A inhibitor for MTAP-deleted tumors; IDE892, a PRMT5 inhibitor; IDE574 selectively inhibits KAT6/7 and is in Phase 1 dose escalation trial for patients with breast, lung, prostate, and colorectal cancers; IDE275 oral small molecule inhibitor of the helicase domain of the Werner protein (WRN) and is in a Phase 1 clinical trial.
In addition, the company offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform.
The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Gilead Sciences, Inc., Novartis, Biocytogen, Cancer Research UK, the University of Manchester, Jiangsu Hengrui Pharmaceuticals Co., Ltd., and Les Laboratoires Servie.
It also has a clinical collaboration agreement with AstraZeneca plc to evaluate IDE849, an antibody-drug conjugate; and clinical collaboration with Roche to evaluate IDE892, IDEAYA's potential best-in-class Phase 1 MTA-cooperative PRMT5 inhibitor, in combination with RG6505, Roche's Phase 1 pan-R
Stock analysis
Ideaya Biosciences Inc (IDYA) currently trades at $30.36, while our estimate is $19.49, 36% below the price, so the stock looks overvalued today.
Show more
Valuation
None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.
Scenario range: $14.62 (bear) to $24.37 (bull), the price of $30.36 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 39/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Ideaya Biosciences Inc reported revenue of $219M in FY2025 versus $27.9M in FY2021, a compound +67.3%/yr. Reported net income was −$114M in FY2025.
Key figures
Market cap $2.8B Mid · P/S ratio 81.1 · EPS (TTM) $−4.26 · Net margin −52.0% · Return on equity −38.5% · Return on assets (EBIT) −18.7% (5-year average) · Operating margin −1,344% · Revenue growth (YoY) −95.1%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 15 out of 100 (low confidence).
What moves the price
The share trades about 29% below its 52-week high and 10% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −36%, IDYA screens richer than that median.
Fair Value
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Insider trades
In the last 6 months, 2 officers or directors sold shares worth $1.4M and none bought.
- SaleYujiro S HataPresident and CEO, Director26,338 shares at $37.41$985,397Oct 6, 202610b5-1 plan
- SaleBriseno Andres RuizChief Accounting Officer9,550 shares at $40.01$382,096Jul 7, 202610b5-1 plan
- BuyJeffrey SteinDirector50,000 shares at $32.96$1.6MMar 2, 2026
Plus 2 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Source: SEC Form 4, as of Nov 16, 2026. All filings at the SEC ↗
Revenue & earnings trend
Earlier news
- IDEAYA Biosciences to Participate in Upcoming November 2026 Investor Relations Events
- IDEAYA Biosciences, Inc. (IDYA) Reports Q3 Loss, Tops Revenue Estimates
- IDEAYA Biosciences Reports Financial Results for the Third Quarter 2026 and Provides a Business Update
- Is IDEAYA Biosciences (IDYA) A Bargain Following Its ESMO 2026 Clinical Data?
Compare Ideaya Biosciences Inc with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 847 stocks
Valuation Multiplesvs Biotechnology median · lower = cheaper
Strength profile in five axes (Snowflake)
VALUE 0: the price sits above our fair-value range.
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Price/FCF by industry
- Debt-to-equity by industry
- Stock screener with 62 metrics
- Undervalued stocks: US Stocks
- Valuation of the USA market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Regeneron Pharmaceuticals, Inc REGN | $952.40 | $1,275 | +34% | vs IDYA |
| Vertex Pharmaceuticals Incorporated VRTX | $537.79 | $592.46 | +10% | vs IDYA |
| Samsung Biologics Co 207940 | 1,423,000 KRW | 1,552,100 KRW | +9% | vs IDYA |
| argenx SE ARGX | $950.95 | $908.40 | −4% | vs IDYA |
| CSL Limited CSL | A$199.55 | A$186.49 | −7% | vs IDYA |
| Moderna, Inc MRNA | $215.27 | $135.64 | −37% | vs IDYA |
| BeOne Medicines AG 6160 | HK$249.40 | HK$152.92 | −39% | vs IDYA |
| Revolution Medicines, Inc RVMD | $166.87 | $88.78 | −47% | vs IDYA |
| Celltrion, Inc 068270 | 214,500 KRW | 74,945 KRW | −65% | vs IDYA |
| Royalty Pharma plc RPRX | $68.53 | $19.01 | −72% | vs IDYA |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Ideaya Biosciences Inc (IDYA) overvalued or undervalued?
What is the fair value of IDYA?
What is the quality score of IDYA?
What is the price target for Ideaya Biosciences Inc (IDYA)?
What is the Ideaya Biosciences Inc stock forecast for 2026?
What is the intrinsic value of Ideaya Biosciences Inc (IDYA)?
Is Ideaya Biosciences Inc stock overvalued or undervalued in 2026?
Is fair value the same as the market price of IDYA?
How much is Ideaya Biosciences Inc worth?
What do the bullish and bearish scenarios say about IDYA?
How solid is the balance sheet of Ideaya Biosciences Inc (IDYA)?
How far is IDYA from its 52-week high?
Which stocks are comparable to Ideaya Biosciences Inc?
Is Ideaya Biosciences Inc stock attractive at the current price?
Is it still worth investing in stocks now?
What is the share price of Ideaya Biosciences Inc (IDYA)?
What should I pay attention to with Ideaya Biosciences Inc right now?
Key figures of Ideaya Biosciences Inc
How large is the market capitalisation of Ideaya Biosciences Inc (IDYA)?
What is the P/S ratio of Ideaya Biosciences Inc (IDYA)?
What are the earnings per share of Ideaya Biosciences Inc (IDYA)?
What is the net margin of Ideaya Biosciences Inc (IDYA)?
What is the return on equity of Ideaya Biosciences Inc (IDYA)?
What is the EBIT return on assets of Ideaya Biosciences Inc (IDYA)?
What is the operating margin of Ideaya Biosciences Inc (IDYA)?
How fast is revenue growing at Ideaya Biosciences Inc (IDYA)?
How much free cash flow does Ideaya Biosciences Inc (IDYA) generate?
How much net cash does Ideaya Biosciences Inc (IDYA) hold?
Watch Ideaya Biosciences Inc in the live analysis
One click puts Ideaya Biosciences Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.